Epidemiological, Clinical and Biological Caracteristics of Patients Presenting With Invasive Meningococcal Disease
Condition: Meningococcal Infections Intervention: Other: There is no intervention Sponsor: Poitiers University Hospital Recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - August 8, 2023 Category: Research Source Type: clinical trials
Study of Tixagevimab/Cilgavimab and Regdanvimab Efficacy for Treatment of COVID-19
Condition: Coronavirus Infections Interventions: Drug: tixagevimab/cilgavimab 150+150 mg; Drug: tixagevimab/cilgavimab 300+300 mg; Drug: regdanvimab Sponsors: City Clinical Hospital No.52 of Moscow Healthcare Department; Gamaleya Research Institute of Epidemiology and Microbiology, Health Ministry of the Russian Federation Active, not recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - August 8, 2023 Category: Research Source Type: clinical trials
Epidemiological, Clinical and Biological Caracteristics of Patients Presenting With Invasive Meningococcal Disease
Condition: Meningococcal Infections Intervention: Other: There is no intervention Sponsor: Poitiers University Hospital Recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - August 8, 2023 Category: Research Source Type: clinical trials
Study of Tixagevimab/Cilgavimab and Regdanvimab Efficacy for Treatment of COVID-19
Condition: Coronavirus Infections Interventions: Drug: tixagevimab/cilgavimab 150+150 mg; Drug: tixagevimab/cilgavimab 300+300 mg; Drug: regdanvimab Sponsors: City Clinical Hospital No.52 of Moscow Healthcare Department; Gamaleya Research Institute of Epidemiology and Microbiology, Health Ministry of the Russian Federation Active, not recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - August 8, 2023 Category: Research Source Type: clinical trials
Epidemiological, Clinical and Biological Caracteristics of Patients Presenting With Invasive Meningococcal Disease
Condition: Meningococcal Infections Intervention: Other: There is no intervention Sponsor: Poitiers University Hospital Recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - August 8, 2023 Category: Research Source Type: clinical trials
Study of Tixagevimab/Cilgavimab and Regdanvimab Efficacy for Treatment of COVID-19
Condition: Coronavirus Infections Interventions: Drug: tixagevimab/cilgavimab 150+150 mg; Drug: tixagevimab/cilgavimab 300+300 mg; Drug: regdanvimab Sponsors: City Clinical Hospital No.52 of Moscow Healthcare Department; Gamaleya Research Institute of Epidemiology and Microbiology, Health Ministry of the Russian Federation Active, not recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - August 8, 2023 Category: Research Source Type: clinical trials
Congenital Syphilis in Switzerland
Condition: Congenital Syphilis Intervention: Other: Epidemiological study Sponsors: University Hospital, Geneva; Fonds national Suisse Completed (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - August 4, 2023 Category: Research Source Type: clinical trials
